Treatment of Pseudotumor Cerebri (Idiopathic Intracranial Hypertension)

Initial Assessment and Risk Stratification

The American Academy of Neurology recommends that all patients with IIH should have thorough documentation of visual acuity, pupil examination, formal visual field assessment, dilated fundal examination to grade papilloedema, and BMI calculation 1
Risk stratification should be based on the presence and severity of papilloedema and visual field defects, according to the American Academy of Neurology 2, 1

The American Academy of Neurology recommends a weight loss program with low-salt diet for all overweight IIH patients, with a goal of 5-10% weight loss 2, 3
Weight loss is the only disease-modifying treatment and should be emphasized even when other treatments are initiated, as stated by the American Academy of Neurology 2, 3

The American Academy of Neurology recommends acetazolamide as the first-line medical therapy for symptomatic patients or those with evidence of visual loss 2

The American Academy of Neurology recommends urgent surgical treatment when there is evidence of declining visual function or severe visual loss at presentation, to preserve vision 2
A temporizing lumbar drain may be used while planning definitive surgical intervention, as suggested by the American Academy of Neurology 2
Ventriculoperitoneal (VP) shunt is the preferred CSF diversion procedure due to lower reported revision rates per patient, according to the American Academy of Neurology 2

The American College of Obstetricians and Gynecologists recommends multidisciplinary communication among relevant experienced clinicians throughout pregnancy, peridelivery, and postpartum period 4, 1
Acetazolamide should be used with caution during pregnancy after a clear risk-benefit assessment, as stated by the American College of Obstetricians and Gynecologists 1

Treatment failure rates include worsening vision after initial stabilization in 34% of patients at 1 year and 45% at 3 years, according to the American Academy of Neurology 2, 3
Follow-up intervals should be based on papilloedema grade and visual field status, with more frequent monitoring for severe or worsening cases, as recommended by the American Academy of Neurology 1, 3

The American Academy of Neurology recommends against using steroids as primary treatment for IIH, as they can worsen the condition and promote weight gain 5
The European Academy of Neurology suggests that surgical intervention is reserved for patients with severe visual loss at presentation or declining visual function despite medical therapy, and CSF diversion procedures should only be considered after medical management failure 6, 7

The International Headache Society recommends close ophthalmologic follow-up based on papilledema severity, with follow-up occurring within 1-3 months for moderate papilledema with visual symptoms 5

The American Academy of Neurology recommends that IIH treatment is not time-limited but rather outcome-driven, focusing on ongoing monitoring, with 34% of patients experiencing treatment failure at 1 year and 45% at 3 years 8

Serial visual field testing and optic disc assessment guide whether to continue, escalate, or potentially taper therapy, with 34% of patients experiencing worsening vision after initial stabilization at 1 year 8
45% of patients show treatment failure at 3 years, necessitating prolonged vigilance 8
One-third to one-half of patients fail to achieve headache improvement, highlighting the need for ongoing management 8

Following venous sinus stenting, long-term antithrombotic therapy is required for longer than 6 months 8
CSF shunt patients require lifelong monitoring, as treatment failure with worsening vision occurs in 34% at 1 year and 45% at 3 years even after surgical intervention 8, 9
Weight loss remains essential even after surgery, as it addresses the underlying disease process 9

Never stop treatment based solely on symptom improvement without objective evidence of papilledema resolution and stable visual fields 8

Continue treatment as long as papilledema persists, with the American Academy of Neurology recommending ongoing monitoring and treatment adjustment as needed 8